104 related articles for article (PubMed ID: 1844824)
21. Evaluation of the argyrophilic nucleolar organizer region, nuclear DNA content and mean nuclear area in transitional cell carcinoma of bladder using a quantitative image analyzer.
Shiina H; Urakami S; Shirakawa H; Shigeno K; Himeno Y; Mizutani M; Igawa M; Ishibe T
Eur Urol; 1996; 29(1):99-105. PubMed ID: 8821699
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic significance of dysplastic urothelial changes for the rate of recurrence in superficial urinary bladder cancer].
Flamm J
Z Urol Nephrol; 1987 Nov; 80(11):641-6. PubMed ID: 3439374
[TBL] [Abstract][Full Text] [Related]
23. Clinical panurothelial disease in patients with superficial bladder tumors: therapeutic implications.
Solsona E; Iborra I; Ricos JV; Monros JL; Rubio J; Almenar S
J Urol; 2002 May; 167(5):2007-11. PubMed ID: 11956428
[TBL] [Abstract][Full Text] [Related]
24. [Prognostic factors in 243 transitional carcinomas of the bladder (II): microscopic parameters of the tumor and staging].
Portillo Martín JA; Val Bernal F; Garijo Ayenza F; Buelta Carrillo L; Martín García B; Hernández Rodríguez R; Gutiérrez Baños JL; Correas Gómez MA; Concepción Masip T; Fernández Gómez JM
Arch Esp Urol; 1991 Mar; 44(2):161-8. PubMed ID: 1867491
[TBL] [Abstract][Full Text] [Related]
25. Classic prognostic factors, flow cytometric data, nuclear morphometric variables and mitotic indexes as predictors in transitional cell bladder cancer.
Lipponen PK; Eskelinen MJ; Kiviranta J; Nordling S
Anticancer Res; 1991; 11(2):911-6. PubMed ID: 2064350
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
27. Role of the argyrophilic nucleolar organizer regions in tumor detection and prognosis.
Pich A; Chiusa L; Margaria E
Cancer Detect Prev; 1995; 19(3):282-91. PubMed ID: 7750118
[TBL] [Abstract][Full Text] [Related]
28. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder.
Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Comino A; Navone R
Cancer; 2002 Aug; 95(4):784-90. PubMed ID: 12209722
[TBL] [Abstract][Full Text] [Related]
29. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
Cai T; Nesi G; Boddi V; Mazzoli S; Dal Canto M; Bartoletti R
Oncol Rep; 2006 Aug; 16(2):329-34. PubMed ID: 16820911
[TBL] [Abstract][Full Text] [Related]
30. Image analysis of Ag-NOR proteins in transitional cell bladder cancer.
Lipponen P
J Pathol; 1993 Dec; 171(4):279-83. PubMed ID: 8158457
[TBL] [Abstract][Full Text] [Related]
31. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
Dekairelle AF; Tombal B; Cosyns JP; Gala JL
Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
[TBL] [Abstract][Full Text] [Related]
32. [Superficial tumor of the bladder with associated carcinoma in situ: new occurrences and increase of tumor stage].
Ojea Calvo A; Nogueira March JL; Figueiredo L; Jamardo D; Benavente J; Castro M
Actas Urol Esp; 1991; 15(2):139-42. PubMed ID: 1807107
[TBL] [Abstract][Full Text] [Related]
33. [Multiple analysis of morphologic factors with prognostic value in transitional cell papillary carcinoma of the bladder. Retrospective study of 571 cases].
Ramos Soler D; Ferrer Lozano J; Navarro Fos S; Llombart-Bosch A
Actas Urol Esp; 1999 Feb; 23(2):119-26. PubMed ID: 10327675
[TBL] [Abstract][Full Text] [Related]
34. [Characterization of nucleolar organizers in carcinomatous mammmary lesions].
Kharrat A; Krichen H; Tabbene F; Sellami M
Arch Inst Pasteur Tunis; 1991; 68(3-4):243-9. PubMed ID: 1824505
[TBL] [Abstract][Full Text] [Related]
35. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis.
Lipponen PK; Aaltomaa S
J Pathol; 1994 Aug; 173(4):333-9. PubMed ID: 7965393
[TBL] [Abstract][Full Text] [Related]
36. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
37. [Significance of AgNOR analysis of urothelial carcinomas].
Helpap B; Loesevitz L
Verh Dtsch Ges Pathol; 1993; 77():222-5. PubMed ID: 7511285
[TBL] [Abstract][Full Text] [Related]
38. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
[TBL] [Abstract][Full Text] [Related]
39. Outcome of very large superficial bladder tumours: a 10-year experience.
Gupta SK; Parr NJ
Scand J Urol Nephrol; 2008; 42(3):243-8. PubMed ID: 18432531
[TBL] [Abstract][Full Text] [Related]
40. Two-dimensional agnor evaluation as a prognostic variable in urinary bladder carcinoma: a different approach via total agnor area/nucleus area per cell.
Cucer N; Imamoglu N; Tozak H; Demirtas H; Sarac F; Tatlisen A; Oztürk F
Micron; 2007; 38(6):674-9. PubMed ID: 17011198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
